Read by QxMD icon Read


Gaia Kiru, Colin Bicknell, Emanuela Falaschetti, Janet Powell, Neil Poulter
BACKGROUND: Although data are inconsistent, angiotensin-converting enzyme inhibitors (ACE-Is) have been associated with a reduced incidence of abdominal aortic aneurysm (AAA) rupture in analysis of administrative databases. OBJECTIVES: (1) To investigate whether or not the ACE-I perindopril (Coversyl arginine, Servier) reduces small AAA growth rate and (2) to evaluate blood pressure (BP)-independent effects of perindopril on small AAA growth and to compare the repeatability of measurement of internal and external aneurysm diameters...
July 2016: Health Technology Assessment: HTA
Sandeep Bansal, D K Chauhan, D Ramesh, Shahid Barmare, Shaibal Chakraborty
OBJECTIVE: Recent hypertension guidelines recommend initiation of treatment with a fixed dose combination of two drugs for more effective and quicker blood pressure control. Few of these have been assessed for efficacy and acceptability. This study examines the short term blood pressure control and acceptability of perindopril, with or without its fixed dose combinations (FDC) with amlodipine and Indapamide in younger patients. METHODS: In a multicentre prospective observational study, patients with stage 1 hypertension were prescribed perindopril 4 mg per day...
November 2014: Indian Heart Journal
Yoann Gut, Mathieu Boiret, Laurent Bultel, Tristan Renaud, Aladine Chetouani, Adel Hafiane, Yves-Michel Ginot, Rachid Jennane
During drug product development, the nature and distribution of the active substance have to be controlled to ensure the correct activity and the safety of the final medication. Matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), due to its structural and spatial specificities, provides an excellent way to analyze these two critical parameters in the same acquisition. The aim of this work is to demonstrate that MALDI-MSI, coupled with four well known multivariate statistical analysis algorithms (PCA, ICA, MCR-ALS and NMF), is a powerful technique to extract spatial and spectral information about chemical compounds from known or unknown solid drug product formulations...
February 2015: Journal of Pharmaceutical and Biomedical Analysis
Alexander M Owen, Sara L Hungerford
No abstract text is available yet for this article.
March 3, 2014: Medical Journal of Australia
Vinay K Bahl, Uday M Jadhav, Hemant P Thacker
BACKGROUND: Current clinical guidelines recognize that the use of more than one agent is necessary to achieve target BP in the majority of patients. The ASCOT-BPLA trial demonstrated that the free combination of amlodipine and perindopril effectively controlled BP and was better than a beta-adrenoceptor antagonist (beta-blocker)/diuretic combination in reducing total mortality and cardiovascular outcomes. OBJECTIVE: To evaluate the efficacy and tolerability of a fixed combination of perindopril and amlodipine in the clinical setting...
2009: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
Jasper J Brugts, Roberto Ferrari, Maarten L Simoons
The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. ACE inhibition by perindopril has two main effects: it inhibits the angiotensin II formation and potentiates bradykinin. Perindopril is one of the ACE inhibitors that has been extensively studied in randomized clinical trials within various patient populations. The clinical efficacy has been demonstrated in patients with hypertension, diabetes mellitus, cerebrovascular disease, stable coronary artery disease (CAD) and heart failure...
April 2009: Expert Review of Cardiovascular Therapy
Kenneth I Ozoemena, Raluca-Ioana Stefan, Jacobus F van Staden, Hassan Y Aboul-Enein
Enantioselective, potentiometric membrane electrodes (EPMEs) based on carbon paste impregnated with different maltodextrins {dextrose equivalent (DE) 4.0-7.0 (I), 13.0-17.0 (II) and 16.5-19.5 (III)} as chiral selectors for the assay of S-perindopril is described. The proposed electrodes could be reliably employed in the assay of S-perindopril raw material and from its pharmaceutical formulation, Coversyl((R)) tablets. The electrode based on maltodextrin (I) showed the best enantioselectivity and time-stability...
March 10, 2004: Talanta
Monique P Curran, Paul L McCormack, Dene Simpson
Perindopril (Coversyl) is a prodrug ester of perindoprilat, an ACE inhibitor. This agent has shown pharmacodynamic effects beyond those responsible for lowering blood pressure (BP), including the improvement of endothelial function and the normalisation of vascular and cardiac structure and function. Perindopril has a well established role in the treatment of patients with hypertension or heart failure. In the EUROPA trial, once-daily perindopril 8 mg prevented cardiovascular events in patients with stable coronary artery disease (CAD) without any apparent heart failure receiving standard recommended therapy...
2006: Drugs
(no author information available yet)
No abstract text is available yet for this article.
September 2005: Cardiovascular Journal of South Africa
S Bavanandan, Z Morad, O Ismail, A Chandran, T Thayaparan, M Singaraveloo
This study was conducted to determine the tolerability and efficacy of valsartan (DIOVAN) compared to perindopril (COVERSYL) in Malaysian patients with mild to moderate hypertension. Two hundred and fifty adult Malaysian patients with a mean sitting diastolic blood pressure of more than 95 mmHg and less than 115 mmHg after a 14 day washout period were randomized to receive either valsartan 80 mg once daily (n=125) or perindopril 4 mg daily (n=125) for eight weeks. The primary end point for efficacy was the change in mean sitting systolic and diastolic blood pressure (SiSBP and SiDBP)...
June 2005: Medical Journal of Malaysia
Lionel Opie, Tony Dalby, D P Naidoo
No abstract text is available yet for this article.
September 2003: Cardiovascular Journal of South Africa
Wendy E Hoy, Zhiqiang Wang, Philip R A Baker, Angela M Kelly
BACKGROUND: Australian Aborigines in remote areas are experiencing an epidemic of renal and cardiovascular disease. In November 1995, we introduced a renal and cardiovascular treatment program into the Tiwi community, which has a three- to fivefold increase in death rates and a recent annual incidence of treated end-stage renal disease (ESRD) of 2760 per million. Our previous study described an estimated 50% reduction in renal failure and all-cause natural deaths in the treatment group through December 31, 1998...
February 2003: Kidney International. Supplement
Wendy E Hoy, Zhiqiang Wang, Philip R A Baker, Angela M Kelly
Australian Aborigines are experiencing an epidemic of renal and cardiovascular disease. In late 1995 we introduced a treatment program into the Tiwi community, which has a three- to fivefold increase in death rates and a recent annual incidence of treated ESRD of 2760 per million. Eligible for treatment were people with hypertension, diabetics with micro or overt albuminuria, and all people with overt albuminuria. Treatment centered around use of perindopril (Coversyl, Servier), with other agents added to reach BP goals; attempts to control glucose and lipid levels; and health education...
July 2003: Journal of the American Society of Nephrology: JASN
(no author information available yet)
No abstract text is available yet for this article.
June 2001: Cardiovascular Journal of South Africa
W Hoy, A Kelly, S Jacups, K McKendry, P Baker, S MacDonald, Z Wang, N Punguatji, J Kerinauia, E Tipiloura, E Tipiloura, C Harrison
An epidemic of cardiovascular disease (CVD) and end stage renal disease (ESRD) has developed among Aborigines in the Northern Territory; CVD deaths increased over the 1980s (tripling among women!), and are now more than five times those of non-Aboriginal people, while ESRD rates are increasing more than 20-fold and are doubling every three to four years. Dialysis costs (>$75,000 per person/year) pose a crisis for health care budgets, but premature mortality is the greater human catastrophe. Health services are not meeting the challenge of timely diagnosis, prevention and containment...
June 1999: Australian and New Zealand Journal of Medicine
G Mesure, A Fallet, J F Chevalier
The authors report a case of acute mania induced by perindopril (Coversyl) in a 57 year old man with no prior history of mental illness. This Angiotensin-Converting Enzyme Inhibitor (ACEI) had been introduced eight days prior to the first signs of excitation, in order to treat recently diagnosed arterial hypertension. Without proof of reintroduction, and on the basis of clinical observations, the attribution appears plausible. Similar observations have been made for other molecules in this class of medication, such as captopril (Lopril)...
September 1995: L'Encéphale
P Fressinaud, G Berrut, H Gallois
Efficacy and acceptability of perindopril (Coversyl) in general practice were evaluated in 23,460 hypertensive patients (52.9% women) during an open six month trial. Patients had essential mild to moderate hypertension (94 mmHg < supine DBP < 115 mmHg) associated or not with obesity (34%), diabetes (12%), hypercholesterolemia (36%), smoking habits (24%). Mean hypertension duration was 6.5 years, 70 p. cent of patients were 50 to 69 years old and 12 p. cent 70 years old or more. Perindopril was started at 4 mg except in older and patients with renal insufficiency (2 mg)...
January 1993: Annales de Cardiologie et D'angéiologie
D Zdrenghea, O Angheloiu, G Icusca, D Timiş
A number of 21 patients with congestive heart failure (CHF) of various etiologies were studied. All patients were subjected to a classical exercise testing (ET) on cycloergometer. The ET was repeated 24 hrs later, 6 hrs after the administration of 2 mg Perindopril (Coversyl). No statistically significant differences in duration and intensity of ET before and after Perindopril were noted for the whole group. But in 9 patients (42.8%) at least one effort level was gained. In these patients the peak double product (DP) was similar before and after Perindopril, but at submaximal effort DP was, at each level, lesser after Perindopril, suggesting a mechanism of afterload reduction in the improvement of effort capacity...
October 1994: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
(no author information available yet)
No abstract text is available yet for this article.
May 1989: Archives des Maladies du Coeur et des Vaisseaux
J L Reid, R J Macfadyen, K R Lees
No abstract text is available yet for this article.
October 5, 1991: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"